Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 13220 participants.

Also called NCT01076764

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 13,220 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01076764
  • EudraCT 2009-016568-36
Main results
  • Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial JAMA, 2013-09-18 DOI, PubMed 23995608
Other papers using this trial's data
  • Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial Circulation. Cardiovascular interventions, 2018-06 DOI, PubMed 29895599
  • Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial Circulation. Cardiovascular interventions, 2021-01 DOI, PubMed 33430604

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Egypt, Estonia, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Indonesia, Israel, Italy, Jordan, Latvia, Lebanon, Lithuania, Malaysia, Mexico, Montenegro, Netherlands, New Zealand, North Macedonia, Norway, Panama, Peru, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Tunisia, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01076764. Randomized; triple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Acronym
TAO
Condition
Acute Coronary Syndrome
Intervention (Drug)
Otamixaban
Intervention (Drug)
Placebo (for Otamixaban)
Intervention (Drug)
UFH
Intervention (Drug)
Placebo (for UFH)
Intervention (Drug)
Eptifibatide
Intervention (Drug)
Placebo (for Eptifibatide)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01076764
Content hash
a6dad61f669819a95598bdc2047331ae9887950b3f5ac43beb4238893971a315